OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.
By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.
hGH fragment 176-191. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Commonly reported | 300 mcg | 1× daily | 0.15 mL | 15 u | 6 doses | |
| Upper reported | 500 mcg | 1× daily | 0.25 mL | 25 u | 4 doses | |
| Trial dose | 1–30 mg | daily, 12 wk | Set by body weight — can't be turned into a single amount to draw | |||
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial | |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 300 mcg | daily | 0.15 mL | 15 u | 14 | 4.2 mg |
| Week 3 onward per 4 weeks from here on |
500 mcg | daily | 0.25 mL | 25 u | 28 | 14 mg |
A C-terminal fragment of human growth hormone investigated as an anti-obesity agent. Human trials were conducted, but efficacy on weight endpoints was not compelling enough to advance, which is itself informative.
Buy AOD-9604this peptideOpens optimal-pep.com in a new tab
Browse the full catalogue, or jump to a neighbouring compound.
A GLP-1/glucagon dual agonist developed primarily in Chinese phase 2/3 programmes.…
A small-molecule NNMT inhibitor rather than a true peptide. Research data show reduced adiposity in diet-induced obesity models. N…
Every compound compared in one table: dose range, how often, half-life and evidence tier.